Tc99m tilmanocept

Phase 2

CARDINAL HEALTH INC (CAH)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Rhabdomyosarcoma

View Full Landscape

Drug Information

Target Indication

Rhabdomyosarcoma

Clinical Trial

NCT02509598

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/19/2014

Lymphoseek

This medicinal product is for diagnostic use only. Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. External imaging and intraoperative evaluation may be performed using a gamma detection device.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CAH

CARDINAL HEALTH INC

Wholesale-Drugs, Proprietaries & Druggists' Sundries•North America•NASDAQ

Related Pipeline

Empagliflozin 10 mgPhase 3

Acute Myocardial Infarction

Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.Phase 2

Galactose Single Point (GSP), Residual Liver Function

Loxoprofen Pain PatchPhase 2

Delayed Onset Muscle Soreness

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts